§ Federal grant opportunity · HT942526PRPIIRA
DoW Parkinson’s, Investigator-Initiated Research Award
Jamie Shortall Grant Officer is accepting applications for DoW Parkinson’s, Investigator-Initiated Research Award. The deadline is November 6, 2026 and the published award range is Award amount not published.
Key facts
- Funder
- Jamie Shortall Grant Officer
- Application deadline
- November 6, 2026
- Award range
- Award amount not published
- Eligibility
- Eligibility criteria are published in the funding opportunity announcement.
- Geography
- United States
- Focus areas
- Research
- Opportunity number
- HT942526PRPIIRA
Program overview
Summary: The fiscal year 2026 (FY26) Parkinson’s Research Program (PRP) Investigator-Initiated Research Award (IIRA) supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to Parkinson’s disease research. Research must address at least one of the four FY26 PRP Focus Areas . Distinctive Features: · Partnering Principal Investigator (PI) Option: Allows for more than one PI. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI(s) will be identified as Partnering PI(s), with a maximum of two Partnering PIs. · Preliminary data are required. · Clinical trials are allowed.
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from Jamie Shortall Grant Officer.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before November 6, 2026, allowing time for registration and validation.
Related grant opportunities
- Fiscal Year (FY) 2027 Department of War (DoW) Defense University Research Instrumentation Program (DURIP)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- ROSES25: C.4 Planetary Science Enabling Facilities
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.